ORBSEN THERAPEUTICS LIMITED

Orbsen Therapeutics Limited is a Galway-based life-science company that is "redefining cell therapy". Leveraging its proprietary platform, Orbsen develops advanced mesenchymal stromal cell treatments aimed at some of the most pressing complications of chronic disease. Its lead candidate, ORBCEL™, is being evaluated in the NEPHSTROM proof-of-concept study for patients with diabetes and advanced chronic kidney disease, with the trial now running across four European Union sites.

The company's pipeline extends to therapies for diabetic foot disease, diabetic kidney disease (DKD) and primary sclerosing cholangitis (PSC). Recent announcements highlight encouraging interim results from the NEPHSTROM trial and ongoing fundraising to progress to Phase II/IIb studies. By combining cutting-edge cell-therapy science with a clear focus on unmet medical needs, Orbsen Therapeutics is positioned to deliver innovative solutions for patients and healthcare providers across Ireland and beyond.